MetaCap

Clene (CLNN) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xilio Therapeutics (XLO) has outperformed Clene (CLNN) over the past year, losing 28.3% versus a loss of 62.0%. Over five years, CLNN leads with a -96.3% price change compared with -97.3% for XLO. Xilio Therapeutics is the larger company by market cap ($53.4 million vs $50.7 million), about 1.1 times the size.

Xilio Therapeutics converts more of its revenue into profit, with a net margin of -80.1% versus -13086.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLNN-62.03%XLO-28.29%
+16%-27%-70%
Nov 21, 20251 yearNov 20, 2026
CLNN-96.51%XLO-97.63%
+10%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLNN versus XLO key metrics
MetricCLNNXLO
Share price$3.52$7.56
Market cap$50.69M$53.40M
1-day change+0.57%-1.11%
YTD return-40.03%-15.63%
1-year return-62.03%-28.29%
5-year return-96.28%-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-2.30$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$200.00K$43.77M
Revenue growth (YoY)-41.52%+589.88%
Net income (latest FY)$-26.17M$-35.04M
Gross margin78.50%—
Operating margin-11541.50%-95.92%
Net margin-13086.50%-80.05%
52-week high$10.84$10.71
52-week low$3.02$6.47
Distance from 52-week high-67.53%-29.41%
Analyst consensusnonenone
Avg. price target upside+814.77%+164.55%
Average volume115.06K11.54K
Shares outstanding14.40M7.06M
Employees7676
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XLO has outperformed CLNN by 33.7 percentage points over the past year.
  • Xilio Therapeutics is more profitable, keeping -80.1 cents of every revenue dollar as net income versus -13086.5 cents for Clene.
  • Xilio Therapeutics grew revenue faster in its latest fiscal year (+589.88% vs -41.52%).

About Clene

CLNN stock →

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

CLNN vs XLO FAQ

Which is bigger, Clene or Xilio Therapeutics?

Xilio Therapeutics (XLO) is larger, with a market capitalization of $53.40M compared with $50.69M for Clene (CLNN).

Which stock has performed better over the past year, CLNN or XLO?

XLO returned -28.29% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.

Are Clene and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons